Abstract
Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.
Keywords:
Clinical guidelines; Diagnostic; Malignant pleural mesothelioma; Treatment.
Publication types
-
Practice Guideline
-
Review
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Asbestos / toxicity
-
Carcinogens / toxicity
-
Combined Modality Therapy / methods
-
Cytoreduction Surgical Procedures
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Gemcitabine
-
Genetic Testing
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Immunotherapy / methods
-
Medical Oncology
-
Mesothelioma, Malignant / diagnosis*
-
Mesothelioma, Malignant / etiology
-
Mesothelioma, Malignant / pathology
-
Mesothelioma, Malignant / therapy*
-
Neoplasm Staging
-
Pemetrexed / therapeutic use
-
Platinum Compounds / therapeutic use
-
Pleural Neoplasms / diagnosis*
-
Pleural Neoplasms / etiology
-
Pleural Neoplasms / pathology
-
Pleural Neoplasms / therapy*
-
Radiotherapy / methods
-
Societies, Medical
-
Spain
-
Vinorelbine / therapeutic use
Substances
-
Antineoplastic Agents
-
Carcinogens
-
Platinum Compounds
-
Pemetrexed
-
Deoxycytidine
-
Asbestos
-
Vinorelbine
-
Gemcitabine